FDA Companion Diagnostic Testing and Implications for Managed Care Pharmacy Directors
Recorded on May 22, 2018
Sponsored by Myriad Genetics Incorporated
FDA designation of a companion diagnostic test has key implications for pharmacy payers. Coordinating medical benefit and pharmacy policies regarding companion diagnostics and pharmaceuticals may be a worthwhile consideration for your plan.
The presentations within this webinar will discuss the OlympiAD data and the resulting FDA companion diagnostic indication for BRACAnalysis CDx in considering treatment options for patients with metastatic breast cancer. Results and analysis from a survey distributed to AMCP members will be discussed within the webinar.
- Johnathan Lancaster, MD, PhD
Chief Medical Officer, Myriad Genetics Incorporated
- Diana Brixner, PhD, RPh, FAMCP
Professor, Executive Director, Pharmacotherapy Outcomes Research Center
Immediate Past-President Academy of Managed Care Pharmacy
This webinar is sponsored, developed and presented by the sponsor. The content of the Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of the Academy of Managed Care Pharmacy.